Découvrez ce que disent vraiment les chiffres — avant le marché
Analyser maintenant
Sentiment des actualités
Les actualités d’aujourd’hui sont-elles un signal d’achat ou un avertissement ?
Analyser maintenant
Acheter / Conserver / Vendre
Faut-il acheter, conserver ou vendre ? Obtenez l’avis de l’IA dès maintenant.
Analyser maintenant
Évaluation des risques
Détectez les risques cachés avant qu’ils n’impactent votre portefeuille.
Analyser maintenant
Juste valeur
Cette action est-elle bon marché, correctement valorisée ou surévaluée ?
Analyser maintenant
Dernières analyses d’IA sur Pacific Edge Limited
Pas de cours
Cours de clôture XNZE 29.04.2026:
0,17 NZD
29.04.2026 05:00
Cours actuels de Pacific Edge Limited
Bourse
Ticker
Devise
Dernier échange
Cours
Variation journalière
NZX
PEB.NZ
NZD
29.04.2026 05:00
0,17 NZD
-0,004 NZD
-2,30 %
UTC
PFGTF
USD
28.04.2026 20:00
0,07 USD
0,00 USD
Flottant et Liquidité des Actions
Flottant Libre90,32 %
Actions en Flottant748,85 M
Actions en Circulation829,14 M
Profil de l'entreprise pour Pacific Edge Limited Action
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. It operates in two segments, Commercial and Research. The company offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer. It is also developing Cxbladder Resolve, a product that identifies those patients who are likely to have aggressive or more advanced bladder cancer; Cxbladder Triage, a product that identifies patients with haematuria who have a low probability of bladder cancer; Cxbladder Detect that enables the non-invasive detection of bladder and other urinary tract cancers; and Cxbladder Monitor, which allows urologists to monitor bladder cancer patients for recurrence of the disease. In addition, the company is developing Cxcolorectal, a prognostic gene signature for patients diagnosed with stage II or stage III colorectal cancers; and products for bladder, gastric, colorectal, endometrial cancers, and melanoma. Pacific Edge Limited was incorporated in 2001 and is headquartered in Dunedin, New Zealand.
